Advanced

A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden

Lindström, Eva LU ; Eberhard, Jonas LU ; Fors, Björn M; Hansen, Karina and Sapin, Christophe (2011) In Nordic Journal of Psychiatry 65(6). p.13-403
Abstract

BACKGROUND: Atypical antipsychotics have similar clinical efficacy in the treatment of schizophrenia; variability in their tolerability represents the discerning factor in treatment choices. Sertindole has a relatively good tolerability profile that favours long-term patient adherence and, therefore, is associated with lower rates of relapse and rehospitalization.

AIM: A model was developed to compare the cost-effectiveness of a 5-year treatment strategy starting with sertindole versus olanzapine, risperidone, aripiprazole or the typical antipsychotic agent, haloperidol.

METHODS: The model was based on published trials and local clinical practice, and considered costs from the perspective of the Swedish National Health... (More)

BACKGROUND: Atypical antipsychotics have similar clinical efficacy in the treatment of schizophrenia; variability in their tolerability represents the discerning factor in treatment choices. Sertindole has a relatively good tolerability profile that favours long-term patient adherence and, therefore, is associated with lower rates of relapse and rehospitalization.

AIM: A model was developed to compare the cost-effectiveness of a 5-year treatment strategy starting with sertindole versus olanzapine, risperidone, aripiprazole or the typical antipsychotic agent, haloperidol.

METHODS: The model was based on published trials and local clinical practice, and considered costs from the perspective of the Swedish National Health Insurance Board.

RESULTS: All atypical agents were clinically superior and more cost-effective than haloperidol with a cost per quality-adjusted life year gained of approximately 490,000 Swedish kroner. Sertindole was associated with the lowest direct and indirect medical costs, driven by its tolerability profile.

CONCLUSIONS: Sertindole represents a useful alternative to the current treatment options available in Sweden.

CLINICAL IMPLICATIONS: The relatively good tolerability profile of sertindole translates into lower costs of schizophrenia management, primarily driven by substantially lower direct and indirect costs. Sertindole appears to be a clinically and cost-effective alternative in the management of patients with schizophrenia in Sweden.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Adult, Antipsychotic Agents, Aripiprazole, Benzodiazepines, Cost-Benefit Analysis, Economics, Pharmaceutical, Female, Haloperidol, Humans, Imidazoles, Indoles, Male, Models, Economic, National Health Programs, Piperazines, Quinolones, Risperidone, Schizophrenia, Sweden
in
Nordic Journal of Psychiatry
volume
65
issue
6
pages
11 pages
publisher
Informa Healthcare
external identifiers
  • scopus:80055097521
ISSN
1502-4725
DOI
10.3109/08039488.2011.590603
language
English
LU publication?
no
id
3aef0e35-2ff5-49fd-839f-e5896d6a2be7
date added to LUP
2016-06-22 16:08:22
date last changed
2017-09-03 05:10:05
@article{3aef0e35-2ff5-49fd-839f-e5896d6a2be7,
  abstract     = {<p>BACKGROUND: Atypical antipsychotics have similar clinical efficacy in the treatment of schizophrenia; variability in their tolerability represents the discerning factor in treatment choices. Sertindole has a relatively good tolerability profile that favours long-term patient adherence and, therefore, is associated with lower rates of relapse and rehospitalization.</p><p>AIM: A model was developed to compare the cost-effectiveness of a 5-year treatment strategy starting with sertindole versus olanzapine, risperidone, aripiprazole or the typical antipsychotic agent, haloperidol.</p><p>METHODS: The model was based on published trials and local clinical practice, and considered costs from the perspective of the Swedish National Health Insurance Board.</p><p>RESULTS: All atypical agents were clinically superior and more cost-effective than haloperidol with a cost per quality-adjusted life year gained of approximately 490,000 Swedish kroner. Sertindole was associated with the lowest direct and indirect medical costs, driven by its tolerability profile.</p><p>CONCLUSIONS: Sertindole represents a useful alternative to the current treatment options available in Sweden.</p><p>CLINICAL IMPLICATIONS: The relatively good tolerability profile of sertindole translates into lower costs of schizophrenia management, primarily driven by substantially lower direct and indirect costs. Sertindole appears to be a clinically and cost-effective alternative in the management of patients with schizophrenia in Sweden.</p>},
  author       = {Lindström, Eva and Eberhard, Jonas and Fors, Björn M and Hansen, Karina and Sapin, Christophe},
  issn         = {1502-4725},
  keyword      = {Adult,Antipsychotic Agents,Aripiprazole,Benzodiazepines,Cost-Benefit Analysis,Economics, Pharmaceutical,Female,Haloperidol,Humans,Imidazoles,Indoles,Male,Models, Economic,National Health Programs,Piperazines,Quinolones,Risperidone,Schizophrenia,Sweden},
  language     = {eng},
  number       = {6},
  pages        = {13--403},
  publisher    = {Informa Healthcare},
  series       = {Nordic Journal of Psychiatry},
  title        = {A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden},
  url          = {http://dx.doi.org/10.3109/08039488.2011.590603},
  volume       = {65},
  year         = {2011},
}